The new multiple myeloma drug ‘Tecvayli’ can now be prescribed in tertiary hospitals in Korea.

According to industry sources, Janssen Korea’s multiple myeloma drug Tecvayli (teclistamab) has passed the drug committee (DC) review of top tertiary hospitals in Korea, including Samsung Medical Center, Seoul National University Hospital, Seoul St. Mary's Hospital, and Seoul Asan Medical Center.

After being approved in Korea in July last year, Tecvayli may be prescribed to treat patients with relapsed or refractory multiple myeloma who have received at least three previous lines of treatment, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody, and have de